SBH
PRAH

Segall Bryant & Hamill’s PRA Health Sciences, Inc. PRAH Stock Holding History

Segall Bryant & Hamill’s Portfolio PRAH Stock Details PRAH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-52,244
Closed -$8.01M – 843
2021
Q1 		$8.01M Buy
52,244
+18,691
+56% +$2.54M 0.08% 244
2020
Q4 		$4.21M Sell
33,553
-614
-2% -$68.7K 0.05% 319
2020
Q3 		$3.47M Buy
34,167
+24,803
+265% +$2.53M 0.05% 311
2020
Q2 		$911K Buy
9,364
+2,140
+30% +$199K 0.02% 460
2020
Q1 		$600K Sell
7,224
-807
-10% -$78.7K 0.01% 557
2019
Q4 		$893K Sell
8,031
-600
-7% -$61.7K 0.01% 542
2019
Q3 		$856K Buy
8,631
+36
+0.4% +$3.58K 0.01% 548
2019
Q2 		$852K Buy
8,595
+35
+0.4% +$3.34K 0.01% 557
2019
Q1 		$944K Buy
8,560
+229
+3% +$23.9K 0.01% 546
2018
Q4 		$766K Sell
8,331
-3,595
-30% -$364K 0.01% 567
2018
Q3 		$1.31M Sell
11,926
-8
-0.1% -$833 0.02% 507
2018
Q2 		$1.11M Buy
+11,934
New +$1.03M 0.02% 519

Other funds holding PRAH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Segall Bryant & Hamill's PRAH Position: Q2 2021 in Review

Segall Bryant & Hamill sold out of PRA Health Sciences, Inc. (PRAH) in Q2 2021, closing a stake of 52,244 shares — an estimated $8.01M sold.

Segall Bryant & Hamill first reported a position in PRAH in Q2 2018 and held it in 12 quarters. The position peaked at $8.01M in Q1 2021. 317 funds tracked by Wall St. Rank hold PRAH as of Q2 2021.

  • Segall Bryant & Hamill reported no remaining PRA Health Sciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Segall Bryant & Hamill sold 52,244 PRA Health Sciences, Inc. shares in Q2 2021, an estimated $8.01M.
  • Segall Bryant & Hamill first reported a position in PRA Health Sciences, Inc. in Q2 2018 and held it in 12 quarters.
  • Segall Bryant & Hamill's PRA Health Sciences, Inc. position peaked at $8.01M in Q1 2021.
  • 317 funds tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q2 2021.

Based on Segall Bryant & Hamill's 13F filing for Q2 2021, filed 12 Aug 2021.